



Table S1. Different therapy lines and eligibility criteria to biologic treatment in patients with psoriasis or psoriatic arthritis.

Disease	Therapy Lines			Eligibility Criteria to Biologic Treatment
	I Line	II Line	III Line	
<i>Psoriasis</i>	Mild psoriasis: Topical corticosteroids • Betamethasone/antibiotics fixed combination • Dexamethasone/antibiotics fixed combination • Clobetasol propionate • Dexamethasone • Desonide • Hydrocortisone • Methylprednisolone • Mometasone furoate • Triamcinolone	Psoriasis moderate-severe grade ^{11,16} : DMARDs: • MTX; • Cyclosporine (severe psoriasis in patients after failure of conventional therapy or when it was not appropriate)	bDMARDs ^{11,16} : • Secukinumab • Ixekizumab • Adalimumab (40-80 mg) • Infliximab • Certolizumab • Etanercept • Ustekinumab • Brodalumab • Risankizumab • Tildrakizumab • Guselkumab	• Inadequate response, contraindications or intolerance to other systemic treatments (e.g. cyclosporine, MTX or PUVA) (Infliximab, Etanercept, Ustekinumab) • Adult patients with moderate or severe plaque psoriasis who were candidates for systemic therapy (Secukinumab, Ixekizumab, Adalimumab)
	Systemic glucocorticoid: • Dexamethasone i.v. Other drugs used in psoriasis (topic administration): • Calcipotriol • Calcipotriol/Betamethasone fixed combination • Calcitriol • Tacalcitol • Tazarotene • Dithranol • Methoxsalen	Systemic glucocorticoid: • Deflazacort Antipsoriatics for systemic use • Acitretin Other antipsoriatic treatments: • PUVA	tsDMARDs ^{11,16} • Apremilast	Comorbidities that could be treated with the same drug (e.g. psoriatic arthritis, Crohn's disease, ulcerative colitis, uveitis) ¹¹
<i>Psoriatic arthritis</i>	csDMARDs: • Leflunomide ¹⁶ • MTX ¹⁶ • Sulfasalazine and Cyclosporine (according to guidelines, but with no indication for psoriatic arthritis in SmPCs ^{16,39})	bDMARDs ¹⁶ : • Abatacept • Adalimumab (40 mg) • Certolizumab pegol • Etanercept • Golimumab • Infliximab	tsDMARDs ^{16,40} : • Apremilast monotherapy or + csDMARDs, in adult patients who have had an inadequate response or who have been intolerant	• Failure or inadequate response at least to a csDMARDs as monotherapy or as fixed combination for 3 months ^{39,41} (bDMARD as monotherapy or +MTX) ¹⁶

<p>NSAIDs⁴⁰</p> <p>Glucocorticoids¹⁶:</p> <ul style="list-style-type: none"> • Deflazacort • Dexamethasone (additional therapy for a short period of time as relief of an acute episode or exacerbation) • Methylprednisolone acetate (suspension for injection) 	<ul style="list-style-type: none"> • Ixekizumab • Secukinumab • Ustekinumab 	<p>to a prior DMARD therapy</p> <ul style="list-style-type: none"> • Patients for whom additional systemic therapy for psoriatic skin lesions is not required (Abatacept) <p>Severe active disease (≥5 swollen joints and high inflammatory indexes) and aggressive (e.g. anatomical joint damage)³⁹</p>
---	--	--

Legend: bDMARDs: Biological Disease Modifying Anti-rheumatic Drugs; csDMARDs: Conventional Synthetic Disease Modifying Anti-rheumatic Drugs; MTX: methotrexate; NSAIDs: Non-steroidal anti-inflammatory drugs; NYHA: New York Heart Association; PUVA: psoralen and ultraviolet A; SmPCs : summary of product characteristics; tsDMARDs: Targeted Synthetic Disease Modifying Anti-rheumatic Drugs.